Literature DB >> 20401299

Rituximab-induced polymorphic ventricular tachycardia.

Joseph T Poterucha1, Mark Westberg, Pamela Nerheim, James P Lovell.   

Abstract

The anti-CD20 monoclonal antibody rituximab is an effective treatment for small lymphocytic lymphoma; however, it has been associated with infusion reactions, including cardiac arrhythmias. Severe cardiac arrhythmia is an adverse reaction that is related to rituximab chemotherapy, and more investigation is warranted into the adverse reactions of rituximab that involve cardiac conduction abnormalities. Herein, we report what we believe to be the 1st case of symptomatic polymorphic ventricular tachycardia to have occurred during an initial infusion of rituximab.

Entities:  

Keywords:  Antibodies, monoclonal/administration & dosage/adverse effects; cardiac pacing, artificial; electrocardiography; heart rate; long QT syndrome/diagnosis/etiology; lymphoma, B-cell/drug therapy; rituximab; tachycardia, ventricular/chemically induced/mortality; tachycardia/diagnosis; torsades de pointes/diagnosis/etiology

Mesh：

Substances：

Year:  2010        PMID： 20401299      PMCID： PMC2851419     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


  14 in total

Review 1.  Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy.

Authors:  R O Dillman
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

2.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.

Authors:  J M Foran; A Z Rohatiner; D Cunningham; R A Popescu; P Solal-Celigny; M Ghielmini; B Coiffier; P W Johnson; C Gisselbrecht; F Reyes; J A Radford; E M Bessell; B Souleau; A Benzohra; T A Lister
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma.

Authors:  Yukihiro Arai; Jiro Tadokoro; Kinuko Mitani
Journal:  Am J Hematol       Date:  2005-04       Impact factor: 10.047

4.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

5.  Impact of atrioventricular node ablation and pacing therapy on clinical course in patients with permanent atrial fibrillation and unstable ventricular tachycardia induced by rapid ventricular response: follow-up study.

Authors:  Dubravko Petrac; Berislav Radićc; Vjekoslav Radeljić; Dusko Hamel; Jaksa Filipović
Journal:  Croat Med J       Date:  2005-12       Impact factor: 1.351

Review 6.  Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes.

Authors:  R Passman; A Kadish
Journal:  Med Clin North Am       Date:  2001-03       Impact factor: 5.456

7.  Impact of left ventricular epicardial and biventricular pacing on ventricular repolarization in normal-heart individuals and patients with congestive heart failure.

Authors:  Rong Bai; Xiao Yun Yang; Yu'e Song; Li Lin; Jia Gao Lü; Chi Keong Ching; Jun Pu; Ruth Kam; Li Fern Hsu; Cun Tai Zhang; Wee Siong Teo; Lin Wang
Journal:  Europace       Date:  2006-11       Impact factor: 5.214

Review 8.  Long QT syndromes and torsade de pointes.

Authors:  S Viskin
Journal:  Lancet       Date:  1999-11-06       Impact factor: 79.321

9.  Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

Authors:  John D Hainsworth; Sharlene Litchy; John H Barton; Gerry Ann Houston; Robert C Hermann; James E Bradof; F Anthony Greco
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

10.  Delayed reduction in left ventricular function following treatment of non-Hodgkin's lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction.

Authors:  Hiroe Kanamori; Yutaka Tsutsumi; Akio Mori; Takahito Kawamura; Shinji Obara; Norihiko Shimoyama; Junji Tanaka; Masahiro Asaka; Masahiro Imamura; Nobuo Masauzi
Journal:  Cardiology       Date:  2006-02-14       Impact factor: 1.869
View more
  10 in total

Review 1.  Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.

Authors:  Cristina Gutierrez; Colleen McEvoy; Laveena Munshi; R Scott Stephens; Michael E Detsky; Joseph L Nates; Stephen M Pastores
Journal:  Crit Care Med       Date:  2020-01       Impact factor: 7.598

Review 2.  Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2022-01-13       Impact factor: 5.606

Review 3.  Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Mauro Galeazzi; Franco Laghi-Pasini
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Illuminating drug action by network integration of disease genes: a case study of myocardial infarction.

Authors:  Rui-Sheng Wang; Joseph Loscalzo
Journal:  Mol Biosyst       Date:  2016-04-26

Review 5.  Cancer Immunotherapies: What the Perioperative Physician Needs to Know.

Authors:  Robert S Ackerman; Aaron R Muncey; Nasrin N Aldawoodi; Rohini Kotha; Rosemarie E Garcia Getting
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.945

6.  Rituximab induced left bundle branch block.

Authors:  Mujeeb Sheikh; Ankush Moza; Blair P Grubb
Journal:  Heart Views       Date:  2015 Jan-Mar

7.  Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.

Authors:  Wisit Cheungpasitporn; Stephen L Kopecky; Ulrich Specks; Kharmen Bharucha; Fernando C Fervenza
Journal:  J Renal Inj Prev       Date:  2016-11-02

Review 8.  Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives.

Authors:  Jialin Duan; Jingwen Tao; Maocai Zhai; Chengpeng Li; Ning Zhou; Jiagao Lv; Lin Wang; Li Lin; Rong Bai
Journal:  Oncotarget       Date:  2018-05-22

9.  Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study.

Authors:  Tian X Zhao; Muhammad Aetesam-Ur-Rahman; Andrew P Sage; Saji Victor; Rincy Kurian; Sarah Fielding; Hafid Ait-Oufella; Yi-Da Chiu; Christoph J Binder; Mikel Mckie; Stephen P Hoole; Ziad Mallat
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

10.  Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma.

Authors:  Lin Gui; Xiaohong Han; Xiaohui He; Yuanyuan Song; Jiarui Yao; Jianliang Yang; Peng Liu; Yan Qin; Shuxiang Zhang; Weijing Zhang; Wenlin Gai; Liangzhi Xie; Yuankai Shi
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.